We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

108 hedge funds and large institutions have $300M invested in Karyopharm Therapeutics in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $4.08M | Put options by funds: $1.3M

100% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 21

0.03% less ownership

Funds ownership: 5.65% → 5.61% (-0.03%)

6% less funds holding

Funds holding: 115 → 108 (-7)

27% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 26

38% less capital invested

Capital invested by funds: $482M → $300M (-$182M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
108
Holders Change
-7
Holders Change %
-6.09%
% of All Funds
2.34%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
19
Increased
42
Reduced
21
Closed
26
Calls
$4.08M
Puts
$1.3M
Net Calls
+$2.78M
Net Calls Change
+$3.12M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$16.8M
2
Citadel Advisors
Citadel Advisors
Florida
+$11.4M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$6.54M
4
PAI
Palo Alto Investors
California
+$4.26M
5
FCM
Frontier Capital Management
Massachusetts
+$3.82M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.4M
2
Franklin Resources
Franklin Resources
California
-$13M
3
State Street
State Street
Massachusetts
-$11.5M
4
DM
Deerfield Management
New York
-$4.45M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$2.16M +$1.01M +9,140 +59%
Two Sigma Investments
27
Two Sigma Investments
New York
$2.02M -$1.95M -17,625 -43%
HM
28
HealthCor Management
New York
$1.73M +$2.19M +19,742 New
SIM
29
Spark Investment Management
New York
$1.56M +$694K +6,262 +54%
Charles Schwab
30
Charles Schwab
California
$1.48M -$110K -988 -6%
CIA
31
Capital Impact Advisors
Massachusetts
$1.4M – – –
TCIM
32
TIAA CREF Investment Management
New York
$1.39M -$1.06M -9,605 -38%
MOACM
33
Mutual of America Capital Management
New York
$1.31M +$662K +5,969 +66%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.28M +$4.21K +38 +0.3%
JP Morgan Chase
35
JP Morgan Chase
New York
$1.22M +$673K +6,070 +78%
BFM
36
Boothbay Fund Management
New York
$1.05M +$1.33M +12,024 New
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$968K – – –
Morgan Stanley
38
Morgan Stanley
New York
$960K +$580K +5,230 +91%
Goldman Sachs
39
Goldman Sachs
New York
$955K +$19.5K +176 +2%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$774K +$286K +2,582 +41%
Connor, Clark & Lunn Investment Management (CC&L)
41
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$765K +$968K +8,730 New
MWNA
42
Marshall Wace North America
New York
$663K +$839K +7,572 New
USAA
43
United Services Automobile Association
Texas
$630K – – –
SSA
44
Schonfeld Strategic Advisors
New York
$612K -$133K -1,200 -15%
CS
45
Credit Suisse
Switzerland
$603K +$276K +2,488 +57%
MCM
46
Moore Capital Management
New York
$584K – – –
PVI
47
Pura Vida Investments
New York
$584K +$739K +6,667 New
Federated Hermes
48
Federated Hermes
Pennsylvania
$536K -$1.49M -13,441 -69%
AllianceBernstein
49
AllianceBernstein
Tennessee
$529K +$195K +1,760 +41%
Prudential Financial
50
Prudential Financial
New Jersey
$517K +$111K +1,000 +20%
1
2
3 4 5

KPTI Hedge Fund Activity: Q1 2019 in Review

108 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2019, worth a combined $300M — down 38% from $482M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of KPTI and 19 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 42 added.

The largest buyer was Millennium Management, adding an estimated $16.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.4M sold.

  • 108 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2019, down from 115 in Q4 2018.
  • Funds reported $300M of Karyopharm Therapeutics stock for Q1 2019, down 38% quarter-over-quarter.
  • 19 funds opened new Karyopharm Therapeutics positions in Q1 2019 and 26 closed out, a net change of -7 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2019 was Millennium Management, an estimated $16.8M added.
  • The largest Karyopharm Therapeutics seller in Q1 2019 was Point72 Asset Management, an estimated $14.4M sold.

Based on aggregated 13F filings for Q1 2019.